Prosecution Insights
Last updated: April 19, 2026

Examiner: VU, JAKE MINH

Tech Center 1600 • Art Units: 1618

This examiner grants 40% of resolved cases

Performance Statistics

40.4%
Allow Rate
-19.6% vs TC avg
827
Total Applications
+27.5%
Interview Lift
1509
Avg Prosecution Days
Based on 787 resolved cases, 2023–2026

Rejection Statute Breakdown

0.4%
§101 Eligibility
22.6%
§102 Novelty
39.9%
§103 Obviousness
21.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19344192 ULTRASOUND MEDIATED DELIVERY OF DRUGS Non-Final OA EXACT Therapeutics AS
17433298 METABOLIC ANALYSIS METHOD Final Rejection BASF SE
19175507 POLYOLS AND POLYOL-BASED HYDROGELS WITH ANTI-CANCER ACTIVITY Non-Final OA THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
19299911 PULSATILE DRUG DELIVERY SYSTEM FOR TREATING MORNING AKINESIA Non-Final OA CONTERA PHARMA A/S
19063950 STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING Non-Final OA Generation Bio Co.
18042779 OPHTHALMIC DYE Non-Final OA Vitreq B.V.
16956956 SOLID DELIVERY COMPOSITION Non-Final OA COSMO TECHNOLOGIES LTD.
17424166 RADIOACTIVE ISOTOPE-LABELED, PHOTO-CROSSLINKABLE HYDROGEL, AND PREPARATION METHOD THEREFOR Non-Final OA SNVIA CO., LTD.
18263826 PHEROMONE DIFFUSING GEL Non-Final OA VIRBAC
18219656 COMPOSITIONS AND METHODS OF DETECTING AND TREATING THROMBOSIS AND VASCULAR PLAQUES Non-Final OA MICROVASCULAR THERAPEUTICS, LLC
17616166 COMPOSITIONS AND METHODS OF DETECTING AND TREATING THROMBOSIS AND VASCULAR PLAQUES Final Rejection MICROVASCULAR THERAPEUTICS, LLC
17612968 NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME Final Rejection NIRvana Sciences Inc.
17439282 Ophthalmic Compositions, and Ocular Uses Thereof, of Indigo Carmine Final Rejection ZEBRA BIOTECH PTY LTD
16864136 LIPID ENCAPSULATED GAS MICROSPHERE COMPOSITIONS AND RELATED METHODS Non-Final OA Lantheus Medical Imaging, Inc.
18189658 Competitive Self-Blocking with Unlabeled Manocept Imaging Agents Non-Final OA Cardinal Health 414, LLC
18009290 ARRDC1-MEDIATED MICROVESICLE-BASED DELIVERY TO THE NERVOUS SYSTEM Non-Final OA Vesigen, Inc.
17926583 BIOACTIVE COMPOSITION FOR KILLING CELLS Non-Final OA AGXX Intellectual Property Holding GmbH
17594243 IMPLANTABLE DEPOTS FOR THE LOCALIZED, SUSTAINED, CONTROLLED RELEASE OF THERAPEUTIC AGENTS TO TREAT CANCER AND RELATED SYMPTOMS AND CONDITIONS Non-Final OA Foundry Therapeutics, Inc.
17433736 DYNAMIC COVALENTLY LINKED HYDROGELS AS STABILIZATION NETWORK PLATFORMS Non-Final OA NANOLY BIOSCIENCE, INC.
17255424 Theranostic Radiophotodynamic Therapy Nanoparticles Non-Final OA The Governers of the University of Alberta
17337357 RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY Final Rejection Fusion Pharmaceuticals Inc.
17149547 METHODS TO INCREASE MILK YIELD AND YIELD OF MILK CONSTITUENTS IN LACTATING RUMINANTS Non-Final OA Nutreco IP Assets B.V.
16644142 SONO-RESPONSIVE EMBOLIC AGENTS Final Rejection IMBIOTECHNOLOGIES LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month